Table 5

Clinical features and response data for the 3 cytokine signatures based cohorts based on bimodal cytokines

CategoryGoodIntermediateBadP
All cases
    AML793447
    MDS571231
New AML
    No.643127
    AHD/second34.4%48.4%44.4%.37
    Favorable cytogenetics10.9%0.0%0.0%.09
    Intermediate cytogenetics42.2%41.9%55.6%
    Unfavorable cytogenetics46.9%58.1%44.4%
    FLT3 mutation11.9%29.2%21.1%.22
Treated new AML
    Treated612825
    Complete remission72.1%53.6%32.0%.005
    Resistant24.6%28.6%48.0%
    Fail3.3%17.9%20.0%
    Relapse56.8%66.7%62.5%.78
    Alive23.0%17.9%8.0%
    Median survival, wk52.337.416.8.003
  • AHD/second indicates antecedent hematologic disorder ≥ 2 months or secondary AML; FLT3 mutation, positive test for an FLT-internal tandem duplication or D835 mutation; and —, not applicable.